• Mashup Score: 6

    Forgot Your Password? Enter the email you used to register to reset your password.

    Tweet Tweets with this article
    • We're on Day 2 of #CompCourse2025 in Seattle! Access presentations from the conference at TCTMD: https://t.co/JqPNIEScxl https://t.co/CzDbk1drvC

  • Mashup Score: 2

    When encountering elderly ACS patients, clinical judgement is important given the risks of bleeding, says Arnold Seto.

    Tweet Tweets with this article
    • Elderly ACS patients may face trade-offs with an early invasive strategy compared with more conservative treatment methods, reducing risks of recurrent events but increasing the chance for bleeding, according to a meta-analysis. More here: https://t.co/SQwkmKgV5R https://t.co/sbvYD2P7gf

  • Mashup Score: 0

    There have been three deaths and no serious injuries tied to a problem affecting detection of the pumps, according to Abiomed.

    Tweet Tweets with this article
    • The @US_FDA has issued a warning about detection problems in Abiomed Impella pumps connected to their Automated Impella Controllers, potentially leading to life-threatening injuries. Read more here: https://t.co/iwYwBqU4Iz https://t.co/PBLq1ynDTN

  • Mashup Score: 9

    Isaac George discusses the one-year clinical results of the novel polymeric leaflet TRIA valve for patients undergoing surgical mitral valve replacement.

    Tweet Tweets with this article
    • In this episode of Heart Valve Matters, @igeorge197 talks about the one-year clinical results of the novel polymeric leaflet TRIA valve for patients undergoing surgical mitral valve replacement, which he presented at this year's #NYValves2025. https://t.co/yBnU1WFE4f https://t.co/jelSajaqlg

  • Mashup Score: 0

    A true test of durability will take many more years, but if the valve holds up, it’s “potentially a game changer,” say surgeons.

    Tweet Tweets with this article
    • Positive early results for a robotically-made polymer surgical valve show an “acceptable safety” profile and stable hemodynamics through 1 year of follow-up in younger patients with symptomatic mitral valve disease. Read more about this innovative device: https://t.co/C6R3VHKt2Q https://t.co/Xii8BQgMS3